Trillium Therapeutics Inc. (NASDAQ:TRIL) ended its last session at $1.49 by Surging 2.05%. The company currently has an average volume of 192.27 Million. Trillium Therapeutics Inc. has its outstanding Shares of 14.69 Million.
Market capitalization is the total market value of all of a company’s outstanding shares. Market capitalization is calculated by multiplying a company’s shares outstanding by the current market price of one share. The investment community uses this figure to determine a company’s size, as opposed to sales or total asset figures. Trillium Therapeutics Inc. (TRIL) has the market capitalization of 21.89 Million.
The (Simple Month Average) SMA20 is at -14.38 percent, its SMA50 Value is -24.61% and SMA200 value is reported as -66.75 Percent. The stock is currently showing its Return on Assets (ROA) value of 0 Percent. The Return on Equity (ROE) and Return on Investment values are 0 percent and 0 percent respectively.
Trillium Therapeutics Inc. (NASDAQ:TRIL) has an annual dividend of $0, while its annual dividend yield is 0%. A dividend is a distribution of a portion of a company’s earnings decided by its BOD (board of directors) specifically for its shareholders. Dividends are mostly given in terms of cash payments, property or as shares of stock.
If we look at the Volatility of the company, Week Volatility is 10.85%, whereas Month Volatility is at 10.26%. The ATR (Average True Range) value is 0.17.
Year to date (YTD) refers to the period beginning the first day of the current calendar or fiscal year up to the current date. YTD information is useful for analyzing business trends or comparing performance data, and the acronym often modifies concepts such as investment returns, earnings and net pay. Year to Date (YTD) performance of Trillium Therapeutics Inc. (NASDAQ:TRIL) is -12.87 percent while its Performance (Week) is -14.86 percent and Performance (month) is at -25.5 percent.
Price Target Analysis:
Price targets show what analysts believes a stock will be worth at the end of a certain time period. Price Target plays a critical role when it comes to the analysis of a Stock. Analysts on average have given a price target of $11.02 to Trillium Therapeutics Inc. stock. (According to data compiled by finviz)
Analyst Recommendations are opinions given by analysts to their clients about whether a given stock is worth buying or not.
According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 1.5 out of the scale from 1 to 5, where 1 stands for Buy and 5 means Sell.
Earnings Estimate Analysis:
The Average Earnings Estimate for the Current Fiscal quarter is $-0.88 per share, according to consensus of 1 analysts. The lower end of the projection is $-0.88 per share, while the higher end is $-0.88 per share.
Now when we talk about Revenue Estimate for the current Fiscal Quarter, Average Revenue Estimate of the stock is projected as $0 where Low Revenue estimate and High Revenue Estimates are $0 and $0 respectively by 1 analysts.